Received:11May2019 | Accepted:3September2019
DOI:10.1002/jcp.29216
REVIEW ARTICLE
‐
Overcoming trastuzumab resistance in HER2 positive breast
cancer using combination therapy
Afshin Derakhshani1* | Zohreh Rezaei2* | Hossein Safarpour3 | Morteza Sabri2 |
Atefeh Mir2 | Mohammad Amin Sanati3 | Fatemeh Vahidian1 |
Ali Gholamiyan Moghadam4 | Ali Aghadoukht5 | Khalil Hajiasgharzadeh1 |
Behzad Baradaran1
1ImmunologyResearchCenter,Tabriz
Abstract
UniversityofMedicalSciences,Tabriz,Iran
2DepartmentofBiology,FacultyofSciences, Human epidermal growth factor receptor 2 (HER2)‐positive breast cancer (BC)
UniversityofSistanandBalouchestan, comprisesaround20–30%ofallBCsubtypesandiscorrelatedwithpoorprognosis.
Zahedan,Iran
For many years, trastuzumab, a monoclonal antibody, has been used to inhibit the
3Cellular&MolecularResearchCenter,
BirjandUniversityofMedicalSciences, HER2activity.Though,themainresistancetotrastuzumabhaschallengedtheuseof
Birjand,Iran
this drug in the management of HER2‐positive BC. Therefore, the determination of
4DepartmentofBiologicalScience,Facultyof
Science,UniversityofDamghan,Damghan, resistance mechanisms and the incorporation of new agents may lead to the
Iran development of a better blockade of the HER family receptor signaling. During the
5DepartmentofBiologicalScience,Facultyof
last few years, some therapeutic drugs have been developed for treating patients
Science,UniversityofKurdistan,Sanandaj,Iran
withtrastuzumab‐resistantHER2‐positiveBCthathavemoreeffectiveinfluencesin
Correspondence
the management of this condition. In this regard, the present study aimed at
ZohrehRezaei,DepartmentofBiology,
FacultyofSciences,UniversityofSistanand reviewing the mechanisms of trastuzumab resistance and the innovative therapies
Balouchestan,Zahedan,Iran. thathave been investigatedintrastuzumab‐resistantHER2‐positiveBC subjects.
Email:z.rezaei222@pgs.usb.ac.ir
BehzadBaradaran,ImmunologyResearch KEYWORDS
Center,TabrizUniversityofMedicalSciences, breastcancer,drugresistance,HER2positive,trastuzumab
Tabriz,Iran.
Email:baradaranb@tbzmed.ac.ir
1 | INTRODUCTION EGFR/HER1, HER2, HER3, and HER4 that promote growth factor‐
related signaling, for example, PI3K‐AKT and RAS‐MAPK pathways
Breastcancer(BC),themostpopulartypeofcancerinfemales,still (Yarden & Sliwkowski, 2001). ErbB receptors embody an extracellular
remainsthesecondimportantcauseofcancer‐associateddeaths,in regionthatincludesfourdomains(i.e.,I/L1,II/CR1,III/L2,andIV/CR2)
spiteofsignificantimprovementsinitstreatment(Derakhshanietal., orderedasrepeatingidenticalsegmentsofatwounitedpart,acytosolic
2019; Siegel, Ma, Zou, & Jemal, 2014). BC can be categorized as a tyrosinekinase,andasinglemembrane‐spanningregion.Afteraligand
heterogeneousdiseaseaccordingtothestatusofmolecularprofiles bindstotheextracellularregionmakescytosolickinasedimerizationand
and microscopic appearances such as estrogen receptor (ER) activation, which leads to auto‐phosphorylation and starting of down-
expressionandHER2amplification(Slamonetal.,1987). streamsignalingevents(Choetal.,2003;Vahidianetal.,2019).
Human epidermal growth factor receptor 2 (HER2), a trans Typically,ontheepithelialcellsurfaces,HER2hasalowexpression
membrane tyrosine kinase receptor, a member of the EGF receptor thatisnecessaryforthenormalprogressinvarioustissueslikeovary,
(EGFR) family, is encoded by the HER2 gene. This family includes breast, liver, lung, central nervous system, and kidney. In contrast,
immunohistochemical analyses have revealed that HER2 is over-
*AfshinDerakhshaniandZohrehRezaeicontributedequallytothiswork. expressed in BC cells, which can extend to two million receptors in
|
3142 ©2019WileyPeriodicals,Inc. wileyonlinelibrary.com/journal/jcp JCellPhysiol.2020;235:3142–3156.
|
DERAKHSHANIETAL. 3143
eachcell. Inmetastatic breastcancer(MBC), the increasedlevelsof andKallioniemi(1994)displayedthattheserumECDofHER2released
HER2arerelatedtoreduceddisease‐freesurvival(Pressetal.,1997). intothecirculationandcanberaisedintheserumofwomenwithMBC.
Atthecellmembrane,thelocalizationofHER2isaheterogeneousand Infact,thephosphorylatedtruncatedreceptorhasbeendistinguishedin
dynamic process regulated by differential rates of endocytosis and approximatelyhalfofthehumanBCserumsamples.AreducedHER2‐
recycling(Bertelsen&Stang,2014;ZRezaei&Derakhshani,2018). ECDinserumisconsideredasapredictorofhostresponseduetoits
Trastuzumab (or Herceptin), was developed as a recombinant association with improved progression‐free survival (Molina et al.,
humanizedmonoclonalantibody(mAb)targetingthedomainfourof 2001).
the HER2. It was produced by Genentech Inc. (San Francisco, CA).
Trastuzumabisamongthehighlysuccessfultargetedtreatmentsfor
2.2 | Internalization and degradation of HER2
BC that selectively exerts its antitumor effects on HER2‐amplified
protein
BC tissues with no impact on tumors with normal expression of
HER2.Whencombinedwithotherchemotherapydrugs,trastuzumab In BC cells that highly expressed HER2, trastuzumab leads to
increases the prognosis of subjects with metastatic diseases and downregulation and degradation of HER2. It is proposed that
decreases the risk of cancer recurrence and death (Drebin, Link, trastuzumab begins internalization and degradation of HER2 by
Stern, Weinberg, & Greene, 1985; S. Paik, Kim, & Wolmark, 2008; encouragingthefunctionoftyrosinekinase‐ubiquitinligasec‐Cbl.It
Seidman et al., 2008; Vogel et al., 2002). Nowadays, choosing the isalsosuggestedthattheconnectionoftrastuzumabtoHER2results
patients who can undergo trastuzumab therapy is based on HER2‐ in c‐Cbl recruitment to the Tyr1112 site where c‐Cbl ubiquitinates
positivityusingprotein‐andDNA‐basedassays(Drebinetal.,1985; HER2andinducesitscleavage(Klapper,Waterman,Sela,&Yarden,
S.Paiketal.,2008;Seidmanetal.,2008;Vogeletal.,2002). 2000). Baldassarre et al. clarified the roles of Endo II (endocytic
Despitetheclinicalefficacyoftrastuzumab,acquiredresistance adapter protein endophilin A2) in HER2‐positive cancer cells. They
tothisantibodychallengestheuseofthisdrug.Hence,overcoming displayed that silencing Endo II can decrease the responses to
trastuzumab resistance can pave the way for effective therapeutic trastuzumabbycausingdefectsinHER2internalization(Figure1).
methodssuggestedforthetherapyofHER2‐positiveBCresistantto
trastuzumab.
2.3 | Inhibition of angiogenesis
Trastuzumabalsoreducesangiogenesis,whichhasshowntoresultin
2 | MECHANISMS OF TRASTUZUMAB theinhibitionofendothelialcellmigrationinvitroandadecreasein
ACTION microvesseldensityinvivo.Theexpressionsofproangiogenicfactors
were inhibited in trastuzumab‐treated tumors, while these factors
Thereismorethanoneantitumormechanismfortrastuzumab.The wereenhancedintheirrespectivecontrols(Klapperetal.,2000).
antibody's direct action is based on receptor downregulation and
intracellular signalings, such as downstream protumorigenic cell
2.4 | Inhibition of DNA repair
signalingandHER2sheddinginhibition.Indirectactionthathasbeen
recommended as a mechanism of action for trastuzumab is the Theparticularmolecularmechanismsusedbycellsfortheinhibitionof
activation of an immune response via antibody‐dependent cellular DNA repair, which are activated by trastuzumab, remain unclear.
cytotoxicity (ADCC; Clynes, Towers, Presta, & Ravetch, 2000). Pietras et al. (1999) suggested that DNA adduct repair induced by
Trastuzumab has a wide range of antimalignancy effects, especially cisplatin is partially inhibited by trastuzumab. Also, in vitro studies
onHER2‐upregulatedtumorcells.Inthisregard,thepresentreview show that trastuzumab can block DNA synthesis after radiation
aimedatstudyingthemolecularmechanismsoftrastuzumabactions (Baselga,Albanell,Molina,&Arribas,2001).Julienetal.proposedthat
againstcancercells. the inhibition of HER2 by trastuzumab markedly affects DNA
interstrand crosslink repair (Table 1). Le et al. (2005) demonstrated
thattrastuzumabcaninduceDNAdamageanddownregulatedPCNA.
2.1 | Inhibition of HER2 ectodomain shedding
In the presence of a PARP inhibitor, low expression of PCNA may
HER2undergoesproteolyticcleavageinitsextracellulardomain(EDC) impairhomologousrecombination(HR)causingsyntheticlethality(Le
inHER2‐overexpressingtumorcellswhichresultsinatruncatedtypeof et al., 2005). García‐Parra et al. (2014) displayed that poly (ADP‐
HER2thatisatypeofreceptorwithouttheextracellularbindingpart ribose)polymerase(PARP)blockersincreasedtheantitumoreffectsof
for trastuzumab. This shortened membrane‐bound fragment of HER2 trastuzumabinvitroandinvivoinHER2BCcancercells.
retainsdownstreamkinaseactivityandcausestrastuzumabresistance
(Hudziaketal.,1989).Christiansonetal.(1998)intheirstudyshowed 2.5 | Antibody‐dependent cellular cytotoxicity
thatthetruncatedreceptorisalsopresentin24humanBCspecimens mediated by Fc
invivo.Also,Fornieretal.(2005)mentionedthatitmightestablisha
convenientapproachformonitoringthepatientsthattakingtrastuzu- ADCCasanimportantextracellularmechanismoftrastuzumabthat
mab‐basedmedication.AnotherstudybyIsola,Holli,Oksa,Teramoto, is able to recruit major effector cells (e.g., NK cells that express
10974652,
2020,
4,
Downloaded
from
by
Constructor
University,
Wiley
Online
Library
on
[16/05/2025].
See
the
Terms
and
Conditions
(
on
Wiley
Online
Library
for
rules
of use;
OA
articles
are
governed
by the
applicable
Creative
Commons
License
|
3144 DERAKHSHANIETAL.
FIGURE 1 InternalizationanddegradationofHER2proteinsbytrastuzumab.Trastuzumabiseffectiveindownregulationanddegradationof
HER2inHER2‐overexpressingbreastcancercells.TrastuzumabbeginsinternalizationanddegradationofHER2byencouragingtheactivityof
tyrosinekinase‐ubiquitinligasec‐Cbl.ItisalsosuggestedthatbindingoftrastuzumabtoHER2leadstorecruitmentofc‐CbltotheTyr1112site
wherec‐CblubiquitinatesHER2andinducesitsdegradation.AllthementionedfactorsarepresentedinFigure1(seethetextforadditional
details)
FcγRIIIA [CD16]) to overexpress HER2 tumor sites. Clynes et al. intumors(Sliwkowskietal.,1999).Moreover,theADCCactivitywas
(2000)suggestedthatADCCwasenhancedinmicelackingFcγRIIB mainly enhanced in BC patients’ serum in the presence of
(inhibitoryreceptor),whileitwasdecreasedinmicedeficientinthe trastuzumab. Arnould et al. (2006) reported that enhancement in
activating Fc receptors (FcγRIIIA). Thus, Fc‐receptor‐dependent severalnaturalkiller cells(NKcells)and cytotoxicproteinssuch as
mechanismscontributemainlytothefunctionofcytotoxicantibodies granzyme B, were observed in tumor samples from women with
TABLE 1 Differentmechanismsoftrastuzumabinbreastcancertherapy
Mechanism Differentfunctions References
Blockingreceptors Receptordownregulationandreduceintracellularsignaling (Claret&Vu,2012;Moasser,2007)
InhibitionofHER2ectodomain PreventionofHER2cleavage (Christiansonetal.,1998;Codony‐Servat,Albanell,
Lopez‐Talavera,Arribas,&Baselga,1999)
Inhibitionofangiogenesis Inhibitionofendothelialcellmigration (Fornieretal.,2005;Lane,Motoyama,Beuvink,&
Hynes,2001)
DegradationofHER2receptors TriggerHER2,internalization,anddegradationby (Claret&Vu,2012;Klapperetal.,2000)
ubiquitination
Theantibody‐dependentcellular Abletorecruitmajoreffectorcells (Nagataetal.,2004;Sliwkowskietal.,1999)
cytotoxicity
InhibitionofDNArepair BlocktheDNAsynthesisafterradiationandeffectonDNA (Baselgaetal.,2001)
interstrandcross‐linkrepair
Effectoncellcycle InhibitionofG1phasecellcycle (Filipitsetal.,2018)
EffectonthePI3Kpathway DirectlyinhibitsEGFRandERBB2activation (Junttilaetal.,2009;Zhangetal.,2011)
10974652,
2020,
4,
Downloaded
from
by
Constructor
University,
Wiley
Online
Library
on
[16/05/2025].
See
the
Terms
and
Conditions
(
on Wiley
Online
Library
for
rules
of
use;
OA
articles
are
governed
by
the
applicable
Creative
Commons
License
|
DERAKHSHANIETAL. 3145
progressive BC after treatment with trastuzumab and docetaxel presumablyinvolvedtheuncouplingmechanismandtheresulting
(Nagataetal.,2004).Itisshownthattrastuzumab‐inducedADCCcan changed trafficking of the receptor and could thus account for
be augmented by increasing NK cell activities, modulating the acquired or primary resistance to trastuzumab (Valabrega et al.,
antibody itself, and inhibiting different proteins such as caspases, 2005).Furthermore,About70%ofwomenwithHER2+MBCwho
CD112R,andTIGIT,histonedeacetylase(HDAC),andAdams(Nami, primarily responded to trastuzumab, showed progress within a
Maadi,&Wang,2018).ThesefindingsproposedthatADCCactsasa year suggesting “secondary” or “acquired” resistance to trastuzu-
mechanism of trastuzumab action, and clarifies an increase in mab(Valabregaetal.,2005).
responsetotrastuzumabinHER2overexpressingcancercells. Interruptionoftheinterplaybetweenthetherapeuticagentsand
their targetproteins is apotential mechanism for the resistanceof
thetargetedantibodies.Themolecularmechanismsfortrastuzumab
2.6 | The effect of trastuzumab on cell cycle
resistance are listed below (Klos et al., 2003; Pietras et al., 1999;
TrastuzumabarrestscellcycleduringG1phasebytheinhibitionof Wenetal.,2006).
proliferation. The cell cycle is arrested by inhibition of proteins’
expression that is related to the cleavage of the cyclin‐dependent 3.1 | Epitope masking
kinase (CDK) blocker p27kip1. On the other hand, assessing p27
3.1.1 | Breast cancer stem cell markers CD44+ and
expression in women with initial stage HER2‐positive BC after
CD24
treatmentwithtrastuzumab.Filipitsetal.(2018)explainedthatusing
a predefined cutoff, a low p27 expression can be associated to Overexpressionofbreastcancerstemcells(BCSC)markersincluding
positiveeffectsoftrastuzumab(Table1). CD44maycausetoinhibitionofthetrastuzumab‐bindingsiteatthe
HER2‐ECD (Martin‐Castillo et al., 2013). It was shown that
trastuzumab decreases the population of the ALDEFLUOR‐positive
2.7 | The effect of trastuzumab on the PI3K
BCSCsintrastuzumab‐sensitiveandHER2‐amplifiedBCcelllinesvia
pathway
blockadeofPI3K/Aktsignaling,butnotintrastuzumab‐resistantcell
The PI3K signaling pathway is one of the pivotal pathways with lines(Korkaya,Paulson,Iovino,&Wicha,2008).Recentstudieshave
significant oncogenic features in different malignancies. BC tumor- shown that the CD44+/CD24− phenotype can be utilized as a
igenesisisassumedtoberelatedtothispathway.Somestudieshave predictivefactoroftrastuzumabresponseandaprognosticfactorfor
proposed that the complex of HER2/HER3/PI3K and PI3K‐AKT the clinical result in patients with HER2+ primary BC (Seo et al.,
signaling pathway have critical roles in cell proliferation in HER2‐ 2016;Figure3A).
amplified cells (Klos et al., 2003). Trastuzumab can block EGFR
signalingthroughbindingtotheextracellularsubdomainIVofHER2
3.1.2 | Mucin‐1 (MUC1)
but,lapatinibreversiblyinteractswiththecytoplasmicATP‐binding
domainofthekinaseandinhibitsphosphorylationofHER2.Reduced The mucin‐1 (MUC‐1) an O‐linked glycosylated polypeptide that
downstream signaling induces p27kip1, and then induces cell cycle undergoes autocleavage to generate two subunits (Kufe, 2013).
arrest and apoptosis (Baselga et al., 2001; Sliwkowski et al., 1999). MUC1‐N is located extracellularly at the cell surface with the
Trastuzumab also can promote dissociation of Src (a nonreceptor MUC1C‐terminal(MUC1‐C)transmembranesubunit(10).MUC1‐C
tyrosinekinase)fromHER2,whichreducesitsactivity.Consequently, acts as an oncoprotein through association with receptor tyrosine
Aktandmammaliantargetofrapamycin(mTOR)wouldbeinhibited kinases (RTK), such as EGFR and HER2, by coupling to their
(Nagataetal.,2004;Figure2). signaling cascades (9). It has been shown that MUC1‐C play a
criticalroleintheactivationoftheHER2pathwaywhichindicatesa
potential approach to revoke trastuzumab resistance (Raina et al.,
3 | MECHANISMS OF TRASTUZUMAB 2014; Figure 3B). Particularly, cell‐penetrating peptides like
RESISTANCE GO‐203 that specifically bind to the MUC1‐C are currently very
effectivetherapyinpreventinggrowthandmakingthedeathofBC
Thecriticalstepfortheimprovementofnewanti‐HER2strategies cells(38).
is recognition of the trastuzumab resistance mechanisms. Just a
thirdofwomenwithHER2‐positiveBCshowaprimaryresponseto
3.1.3 | Mucin‐4 (MUC4)
trastuzumab that indicates “initial” or “inherent” trastuzumab
resistanceinthepatients(Nagataetal.,2004;Z.Rezaei,Sebzari, MembranemucinssuchasMucin‐4(MUC4)candecreasematrix–cell
Kordi‐Tamandani,&Dastjerdi,2019).Thetrastuzumabresistance interactionsandadhesion.MUC4isgenerallyexpressedintheapical
is unlikely to be the result of an intrinsic defect of HER2 surfaceofmammarycells.InBCcells,MUC4canalsostimulateHER2
degradation but it is probably related to impaired HER2 down- signalingthroughanEGF‐likedomainonitsASGP‐2subunit(Clynes
regulation due to its uncoupling from Cbl, causing another and et al., 2000). It is suggested that MUC4 acts as a ligand for HER2,
impaired pattern of endocytosis. Manufacturing of TGFa causinginduced phosphorylation on Tyr1248 residue of HER2 as a
10974652,
2020,
4,
Downloaded
from
by Constructor
University,
Wiley
Online
Library
on
[16/05/2025].
See
the
Terms
and
Conditions
(
on
Wiley
Online
Library
for
rules
of use;
OA
articles
are
governed
by
the
applicable
Creative
Commons
License
|
3146 DERAKHSHANIETAL.
FIGURE 2 TheeffectoftrastuzumabonthePI3Ksignalingpathway.Innumerousdiseases,thePI3Kpathwayisoneoftheessential
signalingpathwayswithsignificantoncogenicfeatures.Ingeneral,tumorigenesisofbreastcancerisassumedtobeassociatedwiththePI3K
pathway.HER2/HER3/PI3KandPI3K‐AKTsignalingpathwaycomplexhavecriticalrolesincellproliferationinHER2‐amplifiedcells.
Trastuzumabandlapatinibcanblockthissignaling,eitherbyinhibitingtheactivityofEGFRandERBB2kinasesdirectlyorthroughERBB2
bindingatthecellsurface.TrastuzumabcanpromotedissociationofSrc(anonreceptortyrosinekinase)fromHER2,whichreducesitsactivity.
Consequently,Aktandmammaliantargetofrapamycin(mTOR)wouldbeinhibited
main phosphorylation target. Therefore, it contributes to the IGFIR interacts with HER2 physically and phosphorylates it in
transforming function of HER2 oncoprotein. MUC4 does not affect trastuzumab‐resistant cells (de Groot et al., 2016). Also, the
theexpressionlevelofHER2receptorcompletely(Nagyetal.,2005; resistancecanbereversedbyinhibitionofIGF‐1Rsignaling.Jerome
Pai et al., 2016). Also, MUC4 has been described to hide the et al. (2006) and Xin et al. (2015) displayed that recombinant IGF‐
trastuzumab‐bindingsitesofHER2bydecreasingitsbindinginvitro bindingprotein‐3(IGFBP3)orprogressiveheat‐promotedexpression
in JIMT‐1 (a de novo trastuzumab‐resistant BC cell line; 18). ofthedominant‐negativeIGF‐1R486/STOPbyinhibitionofIGF‐1R
However, regulation of MUC4 expression through endogenous signalingcansignificantlysensitizecellstotrastuzumab(Figure3D).
modulatorsanditseffectontrastuzumabresistanceinvivoarestill Sanabria‐Figueroa et al. (2015) found that the main biologic effect
unclear(Figure3C). caused by IGF‐1R was an invasion, which was mediated by both
Forkhead box protein M1 (FoxM1) and Src‐focal adhesion kinase
(FAK)signaling.Theystronglyproposedthatcombinationstargeting
3.2 | Activation of the IGF‐IR pathway
therapyofIGF‐1RandHER2cansuppresstheaggressivepotentialin
Trastuzumab resistance is related to the enhanced signaling of the cancer cells that are resistant to trastuzumab via mechanisms that
insulin‐like growth factor‐I receptor (IGF‐IR). In BC cells, increased relatedtotheSrcandFoxM1(Sanabria‐Figueroaetal.,2015).
expression of IGF‐IR could decrease growth arrest of HER2‐
overexpressionmediatedbytrastuzumab,whichmediatedtrastuzu- 3.3 | β2‐ adrenergic receptor signaling
mab resistance (Saisana, Griffin, & May, 2016; Tóth et al., 2016).
Previously,Nahta,Yu,Hung,Hortobagyi,andEsteva(2006)showed β2‐adrenergicreceptor(β2‐AR),isthemainmediatorofcatecholamine‐
thatIGF‐1RandHER2formauniquereceptorcomplexandexhibit induced impacts on the malignant characteristics of the tumor cells
crosstalkinacquiredresistancemodels.Moreover,itwasshownthat (Armaiz‐Pena et al., 2013). Recent research indicated that the
10974652,
2020,
4,
Downloaded
from
by
Constructor
University,
Wiley
Online
Library
on
[16/05/2025].
See
the
Terms
and
Conditions
(
on
Wiley
Online
Library
for
rules
of
use;
OA
articles
are
governed
by the
applicable
Creative
Commons
License
|
DERAKHSHANIETAL. 3147
FIGURE 3 Themolecularmechanismoftrastuzumabresistance.Inepitopemasking,cellsurfacemoleculeslikeCD44,MUC1,andMUC4
(A,B,andCrespectively)hidetheepitopetowhichtrastuzumabbindsandalsoinhibittherecognitionandbindingofHER2bytrastuzumab;
(D)and(E):Receptorcrosstalk,wherecellsurfacereceptorkinasesuchasIGF‐IRandβ2‐ARstimulatetheactivationofHER2signaling;
(F),PTENblocksthePI3Ksignalingcascade.LossofPTENcanactivatecellsurvivalprocesses;(G),caveolaecanmediateendocytosisand
removetheHER2fromcellsurfacewhichinhibitstrastuzumabbinding;(H),lacksubstantialpartsoftheextracellulardomainofHER2which
termedp95HER2,cannaturallyevadeantibodybindingduetotheabsenceoftheextracellulardomain(Seetextfordetails)
expressionofβ2‐ARreverselycorrelateswithtrastuzumabresponsein to trastuzumab. In this regard, PTEN loss and PIK3CA mutations
patientswithHER+BC.Thedatafromthisstudyindicatedthatβ2‐AR correlated with the inferior time of progression and survival in a
can be implemented for the forecast of the therapeutic outcome of study conducted on 256 women with trastuzumab‐treated HER2+
trastuzumab‐basedtherapyinBC(Liuetal.,2016;Figure3E). MBC(Bernsetal.,2007;Razisetal.,2011).
3.4 | Defects in the PTEN‐PI3K/AKT pathway 3.5 | Caveolae
There are many possible mechanisms leading to trastuzumab The availability and stability of cell surface HER2 is the main
resistance, among which the most prevalent one in BC is the predictor of Trastuzumab influence. Intrinsic defects in the
activation of the PI3K/Akt pathway. The main abnormality limiting endocytic machinery are responsible for HER2 downregulation
theactivationofthePI3K/AktpathwayisthelossofPTENfunction whichisassociatedwithunresponsivenesstotrastuzumabtherapy
or gain‐of‐function mutations in PI3KCA. Berns et al. (2007) (Z. Rezaei, Kordi‐Tamandani, & Dastjerdi, 2018; Valabrega et al.,
proposed an advanced method for identifying patients with poor 2005).Caveolae‐mediatedendocytosisissuggestedtobeinvolved
efficacy response to trastuzumab when combining low PTEN intrastuzumabandT–DM1resistance(Chungetal.,2018;Figure
expressionandmutationspresentinoncogenicPIK3CA(Figure3F). 3G). In a recent study, accumulation of HER2 in response to
They also mentioned a relationship between PIK3CA hotspot pharmacological reduction of CAV1 was demonstrated using
mutations and reduced progression time after treatment. Another preclinical models of xenograft and organotypic cultures from
studyshowedacomprehensivefunctionalRNAinterferenceindicat- freshly harvested human tumors. The finding that CAV1 controls
ingPTENasthecentralmediatoroftrastuzumabsensitivityinHER2‐ the cellular distribution of HER2 can have a direct therapeutic
overexpressing BC cell lines. In addition, PTEN knockdown and indicationforantibody‐mediatedtargetingofHER2andmayshed
transfectionofPI3KCAmutantcelllinecanreturntheirinsensitivity lightontheusageoftheseantibodiesfortherapeuticpurposesand
10974652,
2020,
4,
Downloaded
from
by
Constructor
University,
Wiley
Online
Library
on
[16/05/2025].
See
the
Terms
and
Conditions
(
on
Wiley
Online
Library
for
rules
of use;
OA
articles
are
governed
by
the
applicable
Creative
Commons
License
|
3148 DERAKHSHANIETAL.
molecular imaging of HER2+ tumors. It was revealed that the 4 | THERAPEUTIC STRATEGIES
availability of HER2 protein at the cell surface can be tuned by
temporal reduction of cholesterol through lovastatin in a way 4.1 | Anti‐HER2 antibodies
that could serve to boost trastuzumab binding and therapy
4.1.1 | Lapatinib
against HER2+ tumors. This study demonstrated the potential
advantageofusingstatinstodevelopthetherapeuticoutcomesof LapatinibisadoubleEGFR/ErbB2tyrosinekinaseinhibitor(blocking
trastuzumab and HER2‐targeted molecular imaging in the clinics both HER1 and HER2) that links HER1 and HER2 kinase domains,
(Pereiraetal.,2018). especially to the adenosine triphosphate (ATP) binding site. It also
prevents the activation of phosphorylation and receptors actions.
TheactivationofdownstreampathwayslikeMAPKandPI3K/Aktis
3.6 | Expression of p95HER2
blockedinBCcellsleadingtoadecreasedgrowthandproliferationof
Truncated p95HER2 fragments generated with constitutive kinase the cancer cells. Using this data, clinical studies have tested the
activity,revealedresistancetotrastuzumabduetolackoftrastuzu- impacts of lapatinib in combination with trastuzumab on treating
mab‐binding epitopes. Two kinds of mechanisms have been advanced HER2+ BC that does not respond to trastuzumab (Black-
suggested to form the p95HER2 receptor (a) by proteolytic wellet al., 2010; Konecny et al., 2006). The hypothesis behindthis
degradation of the HER2‐ECD and (b) alternative TIS (translation‐ combinatorialstrategyisthedistinctactionmechanismsinhowthese
initiation sites) of the HER2 protein. HER2‐ECD can be generated drugs work. In fact, trastuzumab is a monoclonal antibody, which
intocellcultureorcirculatingmediainseruminvivo.Enhancedlevels preventsHER2receptorfromdimerizing,andlapatinibisatyrosine
ofHER2‐ECDinserumarerelatedtopoorprognosisinprogressive kinaseblocker,whichinhibitsnascentsignalingthroughHERdimers.
BCpatients(Colomeretal.,2000;Hayesetal.,2001;Leitzeletal., Theotheradvantageisthatunliketrastuzumab,lapatinibisasmall
1995; Y. Lin & Clinton, 1991; Pupa et al., 1993; Ruiz et al., 2018; molecule; thus it is much more appropriate to enter to the central
J.Sperindeetal.,2016,2018;Todeschinietal.,2011;Yamauchietal., nervoussystem(CNS)andhasthepotentialtobettercontrolofMBC
1997;Zabrecky,Lam,McKenzie,&Carney,1991;Figure3h).Inthe (Arteagaetal.,2012).
mammary glands of transgenic mice, expression of p95HER2 Also, it can promote trastuzumab dependent ADCC due to the
receptors displayed more aggressive breast tumors compared with accumulationofHER2onthecellsurface.ThedualefficacyofHER2
thatdeterminedbythefull‐lengthreceptor(Louie&Sevigny,2017). inhibitionwithtrastuzumabandlapatinibwasstudiedinthePhaseIII
BC patients received trastuzumab who show overexpression of studyof EGF104900.In thisstudy, patientswith HER2+MBC who
p95HER2,haveagreaterincidenceoflungtumorinvasioncompared indicated progression during trastuzumab therapy were randomly
with patients expressing the full‐length receptor (M. Scaltriti et al., selectedtotakelapatinibinmonotherapyorlapatinibincombination
2007).Kallergietal.(2015)investigatedtheexpressionofp95HER2 with trastuzumab. The combination was led to more satisfying
receptors on circulating tumor cells (CTCs) in both early and outcomes both in progression‐free survival (PFS) and in OS (Black-
advanced BC women. In the MBC, their incidence enhanced and welletal.,2012).
theirpresencewasduetopoorsurvival.
3.7 | The effect of trastuzumab on cell cycle 4.1.2 | Neratinib
Binding of trastuzumab to HER2 with a high affinity can induce NeratinibisadualtyrosinekinaseinhibitorofHER1thatisusedfor
cytostaticeffect,thatisrelatedtoG1arrestanddecreaseofapoptosis the management of different stages of HER2+ BC. Neratinib is an
and cell proliferation as a result of the increase in the level of the irreversibletyrosinekinaseinhibitor,unlikethereversiblenatureof
p27kip1(Baselgaetal.,2001).TheCDKcanbeinhibitedbyP27Kip1 lapatinib,thisdrugcancovalentlybindtotheATP‐bindingsiteofthe
that blocks cyclin E/CDK2 complexes and induces cell cycle arrest. receptorkinase.Cell‐cyclearrestandantiproliferativeimpactsrelate
P27Kip1 could be phosphorylated by Akt and then marked for to the reduction in signaling in the HER2 model systems after
proteasomal destruction. It has been demonstrated that increased therapywithneratinib(Bursteinetal.,2010;Rabindranetal.,2004).
levelsofp27kip1intrastuzumab‐treatedcelllinescausesareduction This drug was examined in research with HER2+ patients who
inCDK2activity(M.Scaltritietal.,2011).PPM1HisrelatedtoThe werepreviouslyexposedtotrastuzumaborhaveneverbeentreated
PP2Cfamilythatconsistsofmetal‐dependentSer/Thrphosphatases. with anti‐HER2 in the past. In Phase II studies, neratinib showed a
S. Tuen et al. explored that PPM1H knockdown might have an well‐toleratedcapacityandsignificantclinicalactivity.The16‐week
important effect on total levels or phosphorylation of HER family survivalrateswere59%forpatientswithpriortrastuzumabtherapy
members and downstream MAPK, PI3K, or cell‐cycle regulatory and 78% for patients with no prior trastuzumab therapy. It has
signaling pathways. They suggested a model through which PPM1H also been shown that trastuzumab is more effective and has a
candephosphorylatetheT187siteonp27andpreventitsubiquityla- longer inhibitory impact than lapatinib. It could also bypass
tion and degradation. Stabilized p27 could inhibit the cell cycle. potentialpathways of resistance(Rabindran etal., 2004; Sharma&
Therefore,PPM1HmayberelatedtopoorpatientoutcomeinBC. Jayanth,2010).
10974652,
2020,
4,
Downloaded
from
by
Constructor
University,
Wiley
Online
Library
on
[16/05/2025].
See
the
Terms
and
Conditions
(
on
Wiley
Online
Library
for
rules
of use;
OA
articles
are
governed
by
the
applicable
Creative
Commons
License
|
DERAKHSHANIETAL. 3149
4.1.3 | Afatinib 4.1.7 | Tucatinib
Afatinib,asmallmoleculedrug,isanErbBfamilyblockerandtyrosine Tucatinib is an orally‐active inhibitor of ErbB‐2, which can reduce
kinaseinhibitor(TKI;Canonicietal.,2018;Sequistetal.,2013;Tsang toxicity,and can improvedose‐intensity and influence. Recentdata
& Finn, 2012). Afatinib has the potential to irreversibly block all indicate considerable advantages of using this drug, especially in
homo‐ and heterodimers ErbB family receptor related to cancer patientswithbrainmetastasis(Pondeetal.,2018;Zhuetal.,2016).
which characterized it as a candidate for modulating sensitivity in
trastuzumab‐resistant BC. In fact, afatinib has displayed clinical
4.1.8 | PF‐05280014
activity in progressive solid tumors and trastuzumab resistance
HER2+ BC (N. U. Lin et al., 2012). Furthermore, dual inhibition of PF‐05280014isunderinvestigationasapotentialherceptin.Recent
HER2 with the combination of trastuzumab and afatinib which is a studieshavereportedthatneoadjuvanttreatmentwithPF‐05280014
TKI, alone or in combination with chemotherapy, is a treatment administered in a mixture with carboplatin and docetaxel showed
approachformetastaticandtrastuzumab‐resistant(Kümler,Tuxen,& non‐inferiorityinpharmacokineticsandcomparabilityinimmunogeni-
Nielsen,2014). city, safety, and efficacy when compared with trastuzumab‐EU in
combinationwithcarboplatinanddocetaxelinpatientswithrespect-
able HER2+ BC (Lammers et al., 2018; J. Paik, 2018; M. D. Pegram
4.1.4 | Pertuzumab
etal.,2019).
Pertuzumabisanothermonoclonalantibody,whichattemptstoblock
ligand‐induced HER2/HER3 heterodimerization (Gradishar, 2012). 4.1.9 | CT‐P6 (Herzuma)
This drug has a temperate antitumor clinical activity and also, it
CT‐P6 is a biosimilar to trastuzumab with same efficacy and
seems to be a very proper synergistic drug combined with
pharmacokineticsand,equivalentimmunogenicityprofilesandsafety
trastuzumab.Thediversemechanismsofactionoftrastuzumaband
(Jeongetal., 2018).Inaveryrecentstudy, ithasbeenshownthat
pertuzumabactcomplementarytoprepareamoreperfectinhibition
CT‐P6actsinaparticularlysimilarmannertotrastuzumabbybinding
insignaltransductionofHER2.Thiscombinedtreatmenthasstrongly
to the HER2 receptor. Altogether, these results support further
increasedantitumorfunctioninxenograftmodelswithareductionin
evidence of the similarity between trastuzumab and CT‐P6 and
the HER protein levels (Scheuer et al., 2009). Cortés et al. (2009)
indicatethepossibleusageofCT‐P6acrosstrastuzumabindications showedthatthecombinationofpertuzumabandtrastuzumabcould
(Jeongetal.,2018).
reversetrastuzumabresistance.Thepatientswhoreceivedpertuzu-
mabmonotherapyaftertrastuzumabhadclinicalbenefitrate(CBR)
and the objective response rates of 3.4% and 10.3%, respectively. 4.1.10 | Margetuximab (MGAH22)
However,inthepatientswhotakethecombinationafterprogression
on trastuzumab, these rates were 17.6% and 41.2%, respectively MargetuximabisanantibodyagainstHER2bindingwithhighaffinity
(Cortésetal.,2009).
tothelow‐andhigh‐affinityformsofCD16A,anFc‐receptorcritical
for ADCC in tumor cells. In a recent study, it was indicated that
margetuximab was generally well tolerated and showed promising
4.1.5 | Poziotinib singleantitumoractivity(Ohetal.,2017;Table2).
Poziotinib is a new, oral pan‐HER kinase blocking agent, which has
4.2 | Antibody–drug conjugates
revealed effective antitumor actions via suppression of HER family
tyrosine kinases activity. This drug has shown significant clinical 4.2.1 | T–DM1
benefitsinheavily‐treatedHER2+MBCs.Biomarkerstudiesanalyz-
Antibody–drugconjugates(ADCs)aretreatmentapproachesforthe
ing pre‐ and on‐treatment biopsies are required to support further
developmentofselectivelydeliverchemo‐therapeuticdrugstoward
significantclinicaloutcomesofpoziotinibinHER2+MBC(Hanetal.,
tumorswhereasnormaltissuetoxicitylimits.ADCscontainatumor‐
2017;Kogaetal.,2018).
targetingantibodyandcytotoxicsmallmolecules(payloads)attached
through a chemical linker (Kim & Kim, 2015). T–DM1 consists of
antibodytrastuzumab,covalentlyattachedbyathioethermolecular
4.1.6 | Pyrotinib
bondtotheantimicrotubulechemotherapyemtansine(DM1;Girish
Pyrotinib is an oral, irreversible dual pan‐ErbB receptor TKI et al., 2012). Lapatanib plus capecitabine was compared in the
acting against HER1, HER2, and HER4. The drug recently acquired EMILIAstudywithTrastuzumabemtansine(T–DM1),whichshowed
conditional approval in China for utilizing in combination an important variation in OS and PFS improvement in patients
with capecitabine for the therapy of the patients with HER2+ treated with the second regimen (Verma et al., 2012). T–DM1
MBC (Ponde, Brandao, El‐Hachem, Werbrouck, & Piccart, 2018; improvedoverallsurvivalcomparedwithlapatinibpluscapecitabine
Zhuetal.,2016). inHER2+MBCpatientsinthePhaseIIIEMILIAstudyfollowingthe
10974652,
2020,
4,
Downloaded
from
by
Constructor
University,
Wiley
Online
Library
on
[16/05/2025].
See
the
Terms
and
Conditions
(
on
Wiley
Online
Library
for
rules
of use;
OA
articles
are
governed
by
the
applicable
Creative
Commons
License
|
3150 DERAKHSHANIETAL.
TABLE 2 HER2tyrosinekinaseinhibitors
Typeofmoleculesandantibodies Mechanismofaction References
Lapatinib BlockingtheHER1andHER2 (Blackwelletal.,2010;Konecnyetal.,2006)
Neratinib BlockingtheHER1andHER2 (Bursteinetal.,2010;Rabindranetal.,2004)
Afatinib TargetingtheHER2andHER4 (Canonicietal.,2018;Sequistetal.,2013;Tsang&
Finn,2012)
Pertuzumab BlockingtheheterodimerizationofHER2withHER3 (Gradishar,2012;Scheueretal.,2009)
Poziotinib Anoralpan‐HERkinaseinhibitor (Hanetal.,2017;Kogaetal.,2018)
Pyrotinib AdualinhibitorofbothEGFRandHER2 (Pondeetal.,2018;Zhuetal.,2016)
Tucatinib SelectivelyinhibitsHER2 (Pondeetal.,2018;Zhuetal.,2016)
PF‐05280014 Trastuzumabbiosimilar (Lammersetal.,2018;J.Paik,2018;M.D.Pegram
etal.,2019)
Margetuximab Trastuzumabbiosimilar (Ohetal.,2017)
Herzuma BindingtotheHER2receptor (Jeongetal.,2018)
(biosimilaroftrastuzumab)
failureoffirst‐linetherapywithtaxaneandtrastuzumab(Sungetal., 4.2.5 | MEDI4276
2018;Vermaetal.,2012).
MEDI4276isaHER2‐targeting,bispecificantibodyspecificallytargets
and binds to two different epitopes on HER2 linked to a new anti‐
microtubuleblocker calledtubulysin. In HER2+ tumor cells including
4.2.2 | SYD‐0985 T–DM1 resistant cells, MEDI4276 indicates increased cytolysis and
cellularinternalization.Athigherdoses,MEDI4276hasclinicalactivity
SYD‐0985,anagentcompoundmadeupoftrastuzumabconjugated
withenhancingthetoxicity(M.Pegrametal.,2018).
with duocarmycin is tested in patients with advanced stomach and
breastcancers(Pondeetal.,2018).Inarecentstudy,itwasproved
thatSYD985isanewADCwithsignificantactivityagainstepithelial 4.3 | PI3K/Akt/mTOR pathway inhibitors
ovariancarcinoma(EOC)andHER2/neuexpression(Menderesetal.,
mTOR is a serine‐threonine protein kinase that modulates cellular
2017).
metabolism through mRNA translation and protein synthesis.
Activation of this pathway is involved in trastuzumab resistance.
Also, some experiments have shown that targeting of mTOR might
4.2.3 | DS‐8201a
reversetrastuzumabresistance.
DS‐8201a, an agent combining an exatecan derivate and an anti‐
HER2 antibody, has alsodemonstrated Phase I results in atotal of 4.3.1 | Perifosine
130patientssufferingfromadvancedBC,withanORRof61.4%in
HER2+patientsand31.6%inHER2‐lowpatients(Pondeetal.,2018). Perifosine is an Akt inhibitor that undergoes clinical tests in the
In experimental studies, DS‐8201a displayed a wider antitumor hematologicalandsolidtumorsofpatients.Duetohavingexcessive
spectrumcomparedwithT–DM1,especiallyagainsttumorswithlow toxicityofAktinhibitorsinexperimentalmodels,anotherstrategyfor
HER2expressing(Doietal.,2017). inhibition of PI3K/Akt signaling is utilized of small molecules that
might inactivate the mTOR pathway. AP23573, RAD001, and CCI‐
779werethreemTORinhibitorswhichevaluatedforclinicaltestfor
the patients with BC and other solid tumors. According to the
4.2.4 | TAK‐522 (XMT‐1522)
previousreports,lowerPTEN‐expressioninbreasttumorscouldlead
TAK‐522 (XMT‐1522) includes a novel, auristatin‐based cytotoxic to decreased response to trastuzumab. Also, drug discovery
payload (Auristatin F‐hydroxypropylamide, AF‐HPA) and a novel programshavebeguntodevelopdirect,moreefficientandlesstoxic
humanIgG1anti‐HER2monoclonalantibody.Currently,TAK‐522is blockers of the Akt kinase family (C.‐H. Lu et al., 2007; Ma et al.,
being tested in phase‐1b trial patients with advanced breast, 2010;Pandolfi,2004).
gastric, lung, and HER2 expressing cancers. In a very recent study,
TAK‐522wasindicatedtobeasapotentialcandidateforcombina-
4.4 | IGF‐1R inhibitors
tion therapies with immune checkpoint modulators in patients
suffering from poorly immunogenic HER2 expressing tumors As mentioned above, interactions and cross‐signaling between
(Khattaretal.,2018). IGF and HER2 receptor families causing alternative signaling
10974652,
2020,
4,
Downloaded
from
by
Constructor
University,
Wiley
Online
Library
on
[16/05/2025].
See
the
Terms
and
Conditions
(
on
Wiley
Online
Library
for
rules
of
use;
OA
articles
are
governed
by
the
applicable
Creative
Commons
License
|
DERAKHSHANIETAL. 3151
network activation and trastuzumab resistance (Nahta et al., treatments.Now,second‐generationofHSP90inhibitorsisinthe
2006). By disrupting the IGF‐1R/HER2 heterodimer, synergistic developmentphaseoftheclinicaltrial(Chandarlapatyetal.,2010;
interactions with trastuzumab and inhibition of IGF1R Giacchettietal.,2006;Milleretal.,2007;Modietal.,2008;Solit&
downstream signaling, experimental models of trastuzumab‐ Chiosis, 2008). Other hsp90 inhibitors such as retaspimycin and
resistant HER2+ BC have restored trastuzumab sensitivity (Tsang AUY922, are now under assessment in the primary phase of
&Finn,2012). clinical trials as single drugs or in combination with trastuzumab
(Tsang&Finn,2012).
4.5 | Bispecific antibodies
4.8 | Network medicine based approaches
Bispecificantibodies(BsAb)aremonoclonalantibodiesrecognizing
two distinct epitopes in tandem, either in different receptors
Thereisagrowinginsightthatwehavetoenhancethecomplexity
or in the same receptor (Kontermann & Brinkmann, 2015).
of our recommended therapies in case of complex mechanisms
MCLA‐128 recognize both HER2 and HER3, causing increased
such as trastuzumab resistance from a gene‐centered to a
ADCC and ZW25 targets two distinct epitopes on the HER2‐ECD network‐centered perspective (Pujol, Mosca, Farrés, & Aloy,
(Yuetal.,2017).
2010; Z. Rezaei et al., 2019). Network‐centric therapeutic
approaches mention targeting entire pathways instead of single
4.6 | Blockade of PD‐1/PD‐L1 immune checkpoint proteins. The aim of these strategies would a combination of
modulators and targets performing on many therapeutic points
Programmeddeath1(PD‐1)performsasareversemodulatorofthe
thatcanmakesynergisticeffectsoperatebyconvergingactionsat
immune system. This coinhibitory receptor is highly expressed in
particularpathwayareas.
tumor‐infiltrating lymphocytes (TIL). PD‐L1 (PD‐1 ligand) is
With the advances in high‐throughput expression profiling
expressed by several cancers including BC. It is reported that
technologies, trastuzumab resistance mechanism is being progres-
targetingofPD‐1/PD‐L1wouldinhibitPD‐1/PD‐L1dependentpath-
sivelydissectedthroughanalysisofBComicsdataforpredictionof
waysincancer.Tcellinfiltrationcouldbeusedaspredictivemarkers
responsetotreatment(Deckeretal.,2018;Wangetal.,2016).For
ofthetrastuzumabefficacy(Denkertetal.,2010).Ithasbeenshown
example,torecognizepathwayslinkedtoresistance,Creedonetal.
thatPD‐1+TILsrelatedtopoorprognosisinHER2+BC(Muenstetal.,
characterized a novel set of epithelial‐to‐mesenchymal transition
2013). Moreover, emerging data have proposed the correlation
(EMT)‐associated proteins linked to HER2‐independent resistance
between the expression of PD‐L1 on tumor cells and response to
using a systems biology approach. They proved that a subset
anti‐PD‐1 therapy (Brahmer et al., 2010; Topalian et al., 2012).
of EMT‐associated genes can be good candidates for prediction of
Experimentalstudiesindicatedthesynergisticeffectoftrastuzumab
BCs prognosis. Moreover, targeting the EMT‐associated kinases
onanti‐PD1antibodies (J. Stagget al.,2011). Otherimmune‐based
effectively inhibited the proliferation of resistant cells. They
therapies,suchasantiCD73,havealsobeeninvestigated.Preclinical
concludedthatinhibitorstothesekinasescanleadtoaninnovative
data recommended that anti CD73 can reduce tumor growth and
approach for the management of HER2‐independent resistance in
metastases(J.Staggetal.,2010).
differentcancers.
4.7 | HSP90 inhibitors
5 | CONCLUSIONS
Heatshockprotein90(HSP90)isamolecularchaperoneandhasa
criticalroleinthematurationandstabilizationofmanyoncogenic
Recent surveys particularly suggest the effect of Trastuzumab on signalingproteins,suchasHER2/ERBB2(Basso,Solit,Munster,&
HER2‐overexpressingBC.Nevertheless,thetrastuzumabresistance
Rosen,2002;Erlichman,Toft,Ames,&Goetz,2003).Inhibitionof
clinical problem is growing progressively important. In this regard,
HSP90 would degrade of HSP90 client proteins (Ehrlich et al.,
the identification of the trastuzumab resistance molecular mechan- 2009). HSP90 inhibitors plus trastuzumab show antitumor func-
tion in HER2+ BC. HER2 overexpression BC cell lines and isms is more essential than ever. Therefore, it is suggested to
recognizethemostappropriateHER2‐targetedtreatmentcombina-
xenograft models subjected to HSP90 inhibitors demonstrated
tion toward the goal of improving overall survival for metastatic
thedegradationofHER2,inhibitionofPI3Ksignalingandgrowth
HER2‐overexpressingBCpatients.
suppression (X. Lu, Xiao, Wang, & Ruden, 2012). Phase I
assessmentoftanespimycin,aninhibitorofHSP90,plustrastuzu-
mab showed a clinical advantage for trastuzumab resistance
ACKNOWLEDGMENT
HER2+ BC patients, with four minor and one partial response. In
PhaseIIofthesurvey,tanespimycinplustrastuzumabexhibiteda ThisstudywassupportedbyTabrizUniversityofMedicalSciences.
response rate of 24% and a clinical benefit rate (CBR) of 57% in We thank our colleagues from Birjand University of Medical
the patients with HER2+ MBC who had failed prior trastuzumab Sciences.
10974652,
2020,
4,
Downloaded
from
by
Constructor
University,
Wiley
Online
Library
on
[16/05/2025].
See
the
Terms
and
Conditions
(
on
Wiley
Online
Library
for
rules
of use;
OA
articles
are
governed
by
the
applicable
Creative
Commons
License
|
3152 DERAKHSHANIETAL.
CONFLICT OF INTERESTS factorreceptor2–positivemetastaticbreastcancer:Finalresultsfromthe
EGF104900study.JournalofClinicalOncology,30(21),2585–2592.
Theauthorsdeclarethattherearenoconflictofinterests. Brahmer,J.R.,Drake,C.G.,Wollner,I.,Powderly,J.D.,Picus,J.,Sharfman,
W. H., … Topalian, S. L. (2010). Phase I study of single‐agent anti‐
programmeddeath‐1(MDX‐1106)inrefractorysolidtumors:Safety,
AUTHOR CONTRIBUTIONS clinical activity, pharmacodynamics, and immunologic correlates.
Journal of Clinical Oncology, 28(19), 3167–3175. 
A.D.andZ.R.devisedthemainconceptualideas.A.D.,H.S.,M.S., 1200/jco.2009.26.7609
andA.M.wrotetheinitialdraftofthemanuscript.A.A.,A.G.,M.A. Burstein,H.J.,Sun,Y.,Dirix,L.Y.,Jiang,Z.,Paridaens,R.,Tan,A.R.,…
S.,andF.V.preparedfiguresandtables.B.BandZ.R.,K.H.reviewed Badwe, R. (2010). Neratinib, an irreversible ErbB receptor tyrosine
kinase inhibitor, in patients with advanced ErbB2‐positive breast
andeditedthemanuscript.B.B.supervisedthestudy.
cancer.JournalofClinicalOncology,28(8),1301–1307.
Canonici,A.,Ivers,L.,Conlon,N.T.,Pedersen,K.,Gaynor,N.,Browne,B.
C., … Crown, J. (2018). HER‐targeted tyrosine kinase inhibitors
DATA AVAILABILITY STATEMENT
enhanceresponsetotrastuzumabandpertuzumabinHER2‐positive
breastcancer.InvestigationalNewDrugs,37,441–451.
Data sharing is not applicable to this article as no new data were
10.1007/s10637‐018‐0649‐y
Chandarlapaty,S.,Scaltriti,M.,Angelini,P.,Ye,Q.,Guzman,M.,Hudis,C.
createdoranalyzedinthisstudy.
A.,…Rosen,N.(2010).InhibitorsofHSP90blockp95‐HER2signaling
intrastuzumab‐resistanttumorsandsuppresstheirgrowth.Oncogene,
29(3),325–334.
ORCID
Cho,H.S.,Mason,K.,Ramyar,K.X.,Stanley,A.M.,Gabelli,S.B.,Denney,
D.W.,Jr.,&Leahy,D.J.(2003).Structureoftheextracellularregionof
AfshinDerakhshani 
HER2 alone and in complex with the herceptin Fab. Nature,
BehzadBaradaran  421(6924),756–760.
Christianson, T. A., Doherty, J. K., Lin, Y. J., Ramsey, E. E., Holmes, R.,
Keenan,E.J.,&Clinton,G.M.(1998).NH2‐terminallytruncatedHER‐
2/neuprotein:Relationshipwithsheddingoftheextracellulardomain
REFERENCES andwithprognosticfactorsinbreastcancer.CancerResearch,58(22),
5123–5129.
Armaiz‐Pena, G. N., Allen, J. K., Cruz, A., Stone, R. L., Nick, A. M., Chung,Y.C.,Chang,C.M.,Wei,W.C.,Chang,T.W.,Chang,K.J.,&Chao,
Lin,Y.G.,…Sood,A.K.(2013).Srcactivationbyβ‐adrenoreceptorsis W. T. (2018). Metformin‐induced caveolin‐1 expression promotes
akeyswitchfortumourmetastasis.NatureCommunications,4,1403. T‐DM1 drug efficacy in breast cancer cells. Scientific Reports, 8(1),
Arnould,L.,Gelly,M.,Penault‐Llorca,F.,Benoit,L.,Bonnetain,F.,Migeon, 3930.
C., … Coudert, B. (2006). Trastuzumab‐based treatment of HER2‐ Vu,T.,&Claret,F.X.(2012).Trastuzumab:Updatedmechanismsofaction
positive breast cancer: An antibody‐dependent cellular cytotoxicity andresistanceinbreastcancer.FrontiersinOncology,2,62.
mechanism?BritishJournalofCancer,94(2),259–267.
Clynes,R.A.,Towers,T.L.,Presta,L.G.,&Ravetch,J.V.(2000).Inhibitory
10.1038/sj.bjc.6602930 Fcreceptorsmodulateinvivocytoxicityagainsttumortargets.Nature
Arteaga,C.L.,Sliwkowski,M.X.,Osborne,C.K.,Perez,E.A.,Puglisi,F.,& Medicine,6(4),443–446.
Gianni,L.(2012).TreatmentofHER2‐positivebreastcancer:Current Codony‐Servat,J.,Albanell,J.,Lopez‐Talavera,J.C.,Arribas,J.,&Baselga,
statusandfutureperspectives.NatureReviewsClinicalOncology,9(1), J. (1999). Cleavage of the HER2 ectodomain is a pervanadate‐
16–32.
activable process that is inhibited by the tissue inhibitor of
Baselga,J.,Albanell,J.,Molina,M.A.,&Arribas,J.(2001).Mechanismof metalloproteases‐1 in breast cancer cells. Cancer Research, 59(6),
action of trastuzumab and scientific update. Paper presented at the 1196–1201.
seminarsinoncology. Colomer,R.,Montero,S.,Lluch,A.,Ojeda,B.,Barnadas,A.,Casado,A.,…
Basso, A.D., Solit,D.B., Munster, P. N., & Rosen, N.(2002). Ansamycin Lloveras, B. (2000). Circulating HER2 extracellular domain and
antibiotics inhibit Akt activation and cyclin D expression in breast resistancetochemotherapyinadvancedbreastcancer.ClinicalCancer
cancercellsthatoverexpressHER2.Oncogene,21(8),1159–1166. Research,6(6),2356–2362.
Berns,K.,Horlings,H.M.,Hennessy,B.T.,Madiredjo,M.,Hijmans,E.M., Cortés,J.,Baselga,J.,Petrella,T.,Gelmon,K.,Fumoleau,P.,Verma,S.,…
Beelen, K., … Bernards, R. (2007). A functional genetic approach Gianni, L. (2009). Pertuzumab monotherapy following trastuzumab‐
identifiesthePI3Kpathwayasamajordeterminantoftrastuzumab basedtreatment:Activityandtolerabilityinpatientswithadvanced
resistance in breast cancer.CancerCell, 12(4), 395–402.  HER2‐positive breast cancer. Journal of Clinical Oncology, 27(15S),
org/10.1016/j.ccr.2007.08.030 1022–1022.
Bertelsen, V., & Stang, E. (2014). The mysterious ways of ErbB2/HER2 de Groot, S., Charehbili, A., van Laarhoven, H. W. M., Mooyaart, A. L.,
trafficking. Membranes, 4(3), 424–446.  Dekker‐Ensink,N.G.,vandeVen,S.,…Kroep,J.R.(2016).Insulin‐like
membranes4030424 growth factor 1 receptor expression and IGF1R 3129G > T
Blackwell, K. L., Burstein, H. J., Storniolo, A. M., Rugo, H., Sledge, G., polymorphism are associated with response to neoadjuvant che-
Koehler, M., … O’Shaughnessy, J. (2010). Randomized study of motherapy in breast cancer patients: Results from the NEOZOTAC
lapatinib alone or in combination with trastuzumab in women with trial (BOOG 2010‐01). Breast Cancer Research, 18(1), 3. 
ErbB2‐positive, trastuzumab‐refractory metastatic breast cancer. org/10.1186/s13058‐015‐0663‐3
JournalofClinicalOncology,28(7),1124–1130.
Decker,J.T.,Hall,M.S.,Blaisdell,R.B.,Schwark,K.,Jeruss,J.S.,&Shea,L.
Blackwell,K.L.,Burstein,H.J.,Storniolo,A.M.,Rugo,H.S.,Sledge,G.,Aktan, D.(2018).DynamicmicroRNAactivityidentifiestherapeutictargets
G.,…O’Shaughnessy,J.(2012).Overallsurvivalbenefitwithlapatinibin in trastuzumab‐resistant HER2+breast cancer. Biotechnology and
combinationwithtrastuzumabforpatientswithhumanepidermalgrowth Bioengineering,115(10),2613–2623.
10974652,
2020,
4,
Downloaded
from
by
Constructor
University,
Wiley
Online
Library
on
[16/05/2025].
See
the
Terms
and
Conditions
(
on
Wiley
Online
Library
for
rules
of
use;
OA
articles
are
governed
by
the
applicable
Creative
Commons
License
|
DERAKHSHANIETAL. 3153
Denkert,C.,Loibl,S.,Noske,A.,Roller,M.,Müller,B.M.,Komor,M.,…von factorinpatientswithmetastaticbreastcancer:CancerandLeukemia
Minckwitz,G.(2010).Tumor‐associatedlymphocytesasanindepen- GroupBStudy8662.ClinicalCancerResearch,7(9),2703–2711.
dent predictor of response to neoadjuvant chemotherapy in breast Hudziak,R.M.,Lewis,G.D.,Winget,M.,Fendly,B.M.,Shepard,H.M.,&
cancer.JournalofClinicalOncology,28(1),105–113. Ullrich,A.(1989).p185HER2monoclonalantibodyhasantiprolifera-
1200/JCO.2009.23.7370 tiveeffectsinvitroandsensitizeshumanbreasttumorcellstotumor
Derakhshani,A.,Vahidian,F.,Alihasanzadeh,M.,Mokhtarzadeh,A.,Lotfi necrosisfactor.MolecularandCellularBiology,9(3),1165–1172.
Nezhad,P.,&Baradaran,B.(2019).Mastcells:Adouble‐edgedsword Isola,J.J.,Holli,K.,Oksa,H.,Teramoto,Y.,&Kallioniemi,O.‐P.(1994).
in cancer.Immunology Letters, 209, 28–35.  Elevated erbB‐2 oncoprotein levels in preoperative and follow‐up
imlet.2019.03.011 serumsamplesdefineanaggressivediseasecourseinpatientswith
Doi,T.,Iwata,H.,Tsurutani,J.,Takahashi,S.,Park,H.,Redfern,C.H.,… breastcancer.Cancer,73(3),652–658.
Iwasa,T.(2017).SingleagentactivityofDS‐8201a,aHER2‐targeting 0142(19940201)73:3<652::AID‐CNCR2820730324>3.0.CO;2‐4
antibody‐drugconjugate,inheavilypretreatedHER2expressingsolid Jeong,S.A.,Choi,J.M.,Park,J.M.,Lee,J.Y.,Lee,S.J.,Lee,S.Y.,…Chang,
tumors.JournalofClinicalOncology,35(15),Suppl108. S.J.(2018).MechanismofactionofthetrastuzumabbiosimilarCT‐P6.
Drebin, J. A., Link, V. C., Stern, D. F., Weinberg, R. A., & Greene, M. I. Expert Opinion on Biological Therapy, 1–11. 
(1985). Down‐modulation of an oncogene protein product and 14712598.2019.1554052
reversion of the transformed phenotype by monoclonal antibodies. Jerome,L.,Alami,N.,Belanger,S.,Page,V.,Yu,Q.,Paterson,J.,…Leyland‐
Cell,41(3),695–706. Jones, B. (2006). Recombinant human insulin‐like growth factor
Ehrlich, E. S., Wang, T., Luo, K., Xiao, Z., Niewiadomska, A. M., bindingprotein3inhibitsgrowthofhumanepidermalgrowthfactor
Martinez, T., … Yu, X. F. (2009). Regulation of Hsp90 client receptor‐2‐overexpressing breast tumors and potentiates herceptin
proteinsbyaCullin5‐RINGE3ubiquitinligase.Proceedingsofthe activityinvivo.CancerResearch,66(14),7245–7252.
NationalAcademyofSciences,106(48),20330–20335. 10.1158/0008‐5472.Can‐05‐3555
org/10.1073/pnas.0810571106 Junttila, T. T., Akita, R. W., Parsons, K., Fields, C., Lewis Phillips, G. D.,
Goetz,M.P.(2003).TheHsp90chaperonecomplexasanoveltargetfor Friedman, L. S., … Sliwkowski, M. X. (2009). Ligand‐Independent
cancertherapy.AnnalsofOncology,14(8),1169–1176. HER2/HER3/PI3K complex is disrupted by trastuzumab and is
10.1093/annonc/mdg316%JAnnalsofOncology effectively inhibited by the PI3K inhibitor GDC‐0941. Cancer Cell,
Filipits, M., Dafni, U., Gnant, M., Polydoropoulou, V., Hills, M., 15(5),429–440.
Kiermaier,A.,…Dowsett,M.(2018).Associationofp27andcyclin Kallergi,G.,Agelaki,S.,Papadaki,M.A.,Nasias,D.,Matikas,A.,Mavroudis,
D1expressionandbenefitfromadjuvanttrastuzumabtreatmentin D., & Georgoulias, V. (2015). Expression of truncated human
HER2‐positive early breast cancer: A transHERA study. Clinical epidermal growth factor receptor 2 on circulating tumor cells of
Cancer Research, 24(13), 3079–3086.  breastcancerpatients.BreastCancerResearch,17(1),113.
1078‐0432.Ccr‐17‐3473 org/10.1186/s13058‐015‐0624‐x
Fornier,M.N.,Seidman,A.D.,Schwartz,M.K.,Ghani,F.,Thiel,R.,Norton, Khattar,M.,Traore,T.,Horton,K.,Gallery,M.,Brauer,P.,Riceberg,J.,…
L.,&Hudis,C.(2005).SerumHER2extracellulardomaininmetastatic Lowinger,T.B.(2018).Synergyofananti‐HER2ADCTAK‐522(XMT‐
breast cancer patients treated with weekly trastuzumab and 1522)incombinationwithanti‐PD1monoclonalantibody(mAb)ina
paclitaxel: Association with HER2 status by immunohistochemistry syngeneicbreastcancermodelexpressinghumanHER2.TheJournalof
andfluorescenceinsituhybridizationandwithresponserate.Annals Immunology,200(1),122–129.
ofOncology,16(2),234–239. Kim,E.G.,&Kim,K.M.(2015).Strategiesandadvancementinantibody‐
García‐Parra, J., Dalmases, A., Morancho, B., Arpí, O., Menendez, S., drug conjugate optimization for targeted cancer therapeutics.
Sabbaghi, M., … Albanell, J. (2014). Poly (ADP‐ribose) polymerase Biomolecules & Therapeutics, 23(6), 493–509. 
inhibition enhances trastuzumab antitumour activity in HER2 over- 4062/biomolther.2015.116
expressing breast cancer. European Journal of Cancer, 50(15), Klapper,L.N.,Waterman,H.,Sela,M.,&Yarden,Y.(2000).Tumor‐inhibitory
2725–2734. antibodiestoHER‐2/ErbB‐2mayactbyrecruitingc‐Cblandenhancing
Giacchetti,S.,Bjarnason,G.,Garufi,C.,Genet,D.,Iacobelli,S.,Tampellini, ubiquitinationofHER‐2.CancerResearch,60(13),3384–3388.
M.,…Lévi,F.(2006).PhaseIIItrialcomparing4‐daychronomodulated Klos,K.S.,Zhou,X.,Lee,S.,Zhang,L.,Yang,W.,Nagata,Y.,&Yu,D.(2003).
therapyversus2‐dayconventionaldeliveryoffluorouracil,leucovorin, CombinedtrastuzumabandpaclitaxeltreatmentbetterinhibitsErbB‐
and oxaliplatin as first‐line chemotherapy of metastatic colorectal 2‐mediated angiogenesis in breast carcinoma through a more
cancer: The European Organisation for Research and Treatment of effective inhibition of Akt than either treatment alone. Cancer,
Cancer Chronotherapy group. Journal of Clinical Oncology, 24(22), 98(7),1377–1385.
3562–3569. Koga,T.,Kobayashi,Y.,Tomizawa,K.,Suda,K.,Kosaka,T.,Sesumi,Y.,…
Girish,S.,Gupta,M.,Wang,B.,Lu,D.,Krop,I.E.,Vogel,C.L.,…Joshi,A. Mitsudomi,T.(2018).ActivityofanovelHER2inhibitor,poziotinib,
(2012).Clinicalpharmacologyoftrastuzumabemtansine(T‐DM1):An for HER2 exon 20 mutations in lung cancer and mechanism of
antibody–drugconjugateindevelopmentforthetreatmentofHER2‐ acquired resistance: An in vitro study. Lung Cancer, 126, 72–79.
positive cancer. Cancer Chemotherapy and Pharmacology, 69(5), 
1229–1240. Konecny,G.E.,Pegram,M.D.,Venkatesan,N.,Finn,R.,Yang,G.,Rahmeh,
Gradishar, W. J. (2012). HER2 therapy–an abundance of riches. New M., … Slamon, D. J. (2006). Activity of the dual kinase inhibitor
EnglandJournalofMedicine,366(2),176–178. lapatinib (GW572016) against HER‐2‐overexpressing and trastuzu-
Han,J.Y.,Lee,K.H.,Kim,S.W.,Min,Y.J.,Cho,E.,Lee,Y.,…Lee,J.S.(2017). mab‐treatedbreastcancercells.CancerResearch,66(3),1630–1639.
AphaseIIstudyofpoziotinibinpatientswithepidermalgrowthfactor Kontermann, R. E., & Brinkmann, U. (2015). Bispecific antibodies. Drug
receptor (EGFR)‐mutant lung adenocarcinoma who have acquired Discovery Today, 20(7), 838–847. 
resistance to EGFR‐tyrosine kinase inhibitors. Cancer Research and 2015.02.008
Treatment,49(1),10–19. Korkaya,H.,Paulson,A.,Iovino,F.,&Wicha,M.S.(2008).HER2regulates
Hayes,D.F.,Yamauchi,H.,Broadwater,G.,Cirrincione,C.T.,Rodrigue,S. themammarystem/progenitorcellpopulationdrivingtumorigenesis
P.,Berry,D.A.,…CancerandLeukemiaGroup,B.(2001).Circulating andinvasion.Oncogene,27(47),6120–6130.
HER‐2/erbB‐2/c‐neu (HER‐2) extracellular domain as a prognostic onc.2008.207
10974652,
2020,
4,
Downloaded
from
by
Constructor
University,
Wiley
Online
Library
on
[16/05/2025].
See
the
Terms
and
Conditions
(
on
Wiley
Online
Library
for
rules
of
use;
OA
articles
are
governed
by
the
applicable
Creative
Commons
License
|
3154 DERAKHSHANIETAL.
Kufe, D. W. (2013). MUC1‐C oncoprotein as a target in breast cancer: trastuzumab (T). Journal of Clinical Oncology, 25(18_suppl),
Activation of signaling pathways and therapeutic approaches. 1115–1115.
Oncogene,32(9),1073–1081. Moasser,M.M.(2007).TargetingthefunctionoftheHER2oncogenein
Kümler,I.,Tuxen,M.K.,&Nielsen,D.L.(2014).Asystematicreviewof human cancer therapeutics. Oncogene, 26(46), 6577–6592. https://
dual targeting in HER2‐positive breast cancer. Cancer Treatment doi.org/10.1038/sj.onc.1210478
Reviews,40(2),259–270. Modi,S.,Sugarman,S.,Stopeck,A.,Linden,H.,Ma,W.,Kersey,K.,…Hudis,
Lammers,P.E.,Dank,M.,Masetti,R.,Abbas,R.,Hilton,F.,Coppola,J.,& C.A.(2008).PhaseIItrialoftheHsp90inhibitortanespimycin(Tan)+
Jacobs,I.(2018).NeoadjuvantPF‐05280014(apotentialtrastuzumab trastuzumab(T)inpatients(pts)withHER2‐positivemetastaticbreast
biosimilar) versus trastuzumab for operable HER2+ breast cancer. cancer(MBC).JournalofClinicalOncology,26(15),1027–1027.https://
British Journal of Cancer, 119(3), 266–273.  doi.org/10.1200/jco.2008.26.15_suppl.1027
s41416‐018‐0147‐1 Molina, M. A., Codony‐Servat, J., Albanell, J., Rojo, F., Arribas, J., &
Lane,H.,Motoyama,A.,Beuvink,I.,&Hynes,N.E.(2001).Modulationof Baselga, J. (2001). Trastuzumab (herceptin), a humanized anti‐Her2
p27/Cdk2 complex formation through 4D5‐mediated inhibition of receptor monoclonal antibody, inhibits basal and activated Her2
HER2receptorsignaling.AnnalsofOncolgy,12(Suppl_1),S21–S22. ectodomaincleavageinbreastcancercells.CancerResearch,61(12),
Le,X.‐F.,Lammayot,A.,Gold,D.,Lu,Y.,Mao,W.,Chang,T.,…Bast,R.C. 4744–4749.
(2005).Genesaffectingthecellcycle,growth,maintenance,anddrug Muenst,S.,Soysal,S.D.,Gao,F.,Obermann,E.C.,Oertli,D.,&Gillanders,
sensitivity are preferentially regulated by Anti‐HER2 antibody W.E. (2013). Thepresence of programmed death 1(PD‐1)‐positive
through phosphatidylinositol 3‐kinase‐AKT signaling. Journal of tumor‐infiltrating lymphocytes is associated with poor prognosis in
BiologicalChemistry,280(3),2092–2104. human breast cancer. Breast Cancer Research and Treatment, 139(3),
Leitzel,K.,Teramoto,Y.,Konrad,K.,Chinchilli,V.M.,Volas,G.,Grossberg, 667–676.
H.,… Lipton,A.(1995).Elevatedserum c‐erbB‐2antigenlevelsand Nagata, Y., Lan, K. H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., …
decreasedresponsetohormonetherapyofbreastcancer.Journalof Yu, D. (2004). PTEN activation contributes to tumor inhibition by
ClinicalOncology,13(5),1129–1135. trastuzumab, and loss of PTEN predicts trastuzumab resistance in
Lin,N.U.,Winer,E.P.,Wheatley,D.,Carey,L.A.,Houston,S.,Mendelson, patients. Cancer Cell, 6(2), 117–127. 
D.,…Hickish,T.(2012).AphaseIIstudyofafatinib(BIBW2992),an 2004.06.022
irreversible ErbB family blocker, in patients with HER2‐positive Nagy,P.,Friedländer,E.,Tanner,M.,Kapanen,A.I.,Carraway,K.L.,Isola,
metastaticbreastcancerprogressingaftertrastuzumab.BreastCancer J.,&Jovin,T.M.(2005).Decreasedaccessibilityandlackofactivation
ResearchandTreatment,133(3),1057–1065. of ErbB2 in JIMT‐1, a herceptin‐resistant, MUC4‐expressing breast
s10549‐012‐2003‐y cancercellline.CancerResearch,65(2),473–482.
Lin,Y.Z.,&Clinton,G.M.(1991).AsolubleproteinrelatedtotheHER‐2 Nahta,R.,Yu,D.,Hung,M.C.,Hortobagyi,G.N.,&Esteva,F.J.(2006).
proto‐oncogene product is released from human breast carcinoma Mechanismsofdisease:UnderstandingresistancetoHER2‐targeted
cells.Oncogene,6(4),639–643. therapyinhumanbreastcancer.NatureClinicalPracticeOncology,3(5),
Liu,D.,Yang,Z.,Wang,T.,Yang,Z.,Chen,H.,Hu,Y.,…Guo,N.(2016).β2‐ 269–280.
AR signaling controls trastuzumab resistance‐dependent pathway. Nami,B.,Maadi,H.,&Wang,Z.(2018).Mechanismsunderlyingtheaction
Oncogene,35(1),47–58. and synergism of trastuzumab and pertuzumab in targeting HER2‐
Louie, M. C., & Sevigny, M. B. (2017). Steroid hormone receptors as positivebreastcancer.Cancers,10(10),342.
prognostic markers in breast cancer. American Journal of Cancer cancers10100342
Research,7(8),1617–1636. Oh,D.Y.,Im,S.A.,Bang,Y.J.,Giaccone,G.,Burris,H.A.,Bauer,T.M.,…
Lu,C.‐H.,Wyszomierski,S.L.,Tseng,L.‐M.,Sun,M.‐H.,Lan,K.‐H.,Neal, Stewart,S.J.(2017).First‐in‐humanphase1studyofmargetuximab
C. L., … Yu, D. (2007). Preclinical testing of clinically applicable (MGAH22),anFc‐modifiedchimericmonoclonalantibody,inpatients
strategies for overcoming trastuzumab resistance caused by PTEN withHER2‐positiveadvancedsolidtumors.AnnalsofOncology,28(4),
deficiency.ClinicalCancerResearch,13(19),5883–5888. 855–861.doi:10.1093/annonc/mdx002%JAnnalsofOncology.
Lu,X.,Xiao,L.,Wang,L.,&Ruden,D.M.(2012).Hsp90inhibitorsanddrug Pai, P., Rachagani, S., Lakshmanan, I., Macha, M. A., Sheinin, Y.,
resistanceincancer:Thepotentialbenefitsofcombinationtherapies Smith, L. M., … Batra, S. K. (2016). The canonical Wnt pathway
of Hsp90 inhibitors and other anti‐cancer drugs. Biochemical regulates the metastasis‐promoting mucin MUC4 in pancreatic
Pharmacology, 83(8), 995–1004.  ductal adenocarcinoma. Molecular Oncology, 10(2), 224–239.
11.011 
Ma,J.,Meng,Y.,Kwiatkowski,D.J.,Chen,X.,Peng,H.,Sun,Q.,…Zhang,H. Paik,J.(2018).PF‐05280014:Atrastuzumabbiosimilar.BioDrugs,32(5),
(2010).Mammaliantargetofrapamycinregulatesmurineandhuman 515–518.
cell differentiation through STAT3/p63/Jagged/Notch cascade. Jour- Paik, S., Kim, C., & Wolmark, N. (2008). HER2 status and benefit from
nalofClinicalInvestigation,120(1),103–114. adjuvanttrastuzumabinbreastcancer.NewEnglandJournalofMedicine,
Martin‐Castillo, B., Oliveras‐Ferraros, C., Vazquez‐Martin, A., Cufí, S., 358(13),1409–1411.
Moreno,J.M.,Corominas‐Faja,B.,…Menendez,J.A.(2013).Basal/ Pandolfi,P.P.(2004).Breastcancer—lossofPTENpredictsresistanceto
HER2breastcarcinomas:Integratingmoleculartaxonomywithcancer treatment.NewEnglandJournalofMedicine,351(22),2337–2338.
stem cell dynamics to predict primary resistance to trastuzumab Pegram, M., Hamilton, E., Tan, A. R., Storniolo, A. M., Elgeioushi, N.,
(Herceptin). Cell Cycle, 12(2), 225–245.  Marshall,S.,…Patel,M.(2018).47OPhase1studyofbispecificHER2
23274 antibody‐drugconjugateMEDI4276inpatientswithadvancedHER2‐
Menderes, G., Bonazzoli, E., Bellone, S., Black, J., Altwerger, G., positive breast or gastric cancer. Annals of Oncology, 29(suppl_3),
Masserdotti,A.,…Santin,A.D.(2017).SYD985,anovelduocarmy- 
cin‐basedHER2‐targetingantibody‐drugconjugate,showspromising Pegram,M.D.,Bondarenko,I.,Zorzetto,M.M.C.,Hingmire,S.,Iwase,H.,
antitumor activity in epithelial ovarian carcinoma with HER2/Neu Krivorotko,P.V.,…Tan‐Chiu,E.(2019).PF‐05280014(atrastuzumab
expression.GynecologicOncology,146(1),179–186. biosimilar)pluspaclitaxelcomparedwithreferencetrastuzumabplus
1016/j.ygyno.2017.04.023 paclitaxelforHER2‐positivemetastaticbreastcancer:Arandomised,
Miller,K.,Rosen,L.,Modi,S.,Schneider,B.,Roy,J.,Chap,L.,…Hudis,C. double‐blindstudy.BritishJournalofCancer,120(2),172–182.https://
(2007). Phase I trial of alvespimycin (KOS‐1022; 17‐DMAG) and doi.org/10.1038/s41416‐018‐0340‐2
10974652,
2020,
4,
Downloaded
from
by
Constructor
University,
Wiley
Online
Library
on
[16/05/2025].
See
the
Terms
and
Conditions
(
on
Wiley
Online
Library
for
rules
of
use;
OA
articles
are
governed
by
the
applicable
Creative
Commons
License
|
DERAKHSHANIETAL. 3155
Pereira,P.M.R., Sharma, S.K.,Carter, L.M.,Edwards, K.J.,Pourat,J., cells via Src‐focal adhesion kinase and forkhead box protein M1.
Ragupathi, A., … Lewis, J. S. (2018). Caveolin‐1 mediates cellular MolecularPharmacology,87(2),150–161.
distributionofHER2andaffectstrastuzumabbindingandtherapeutic 114.095380
efficacy.NatureCommunications,9(1),5137. Scaltriti,M.,Eichhorn,P.J.,Cortés,J.,Prudkin,L.,Aura,C.,Jiménez,J.,…
s41467‐018‐07608‐w Baselga, J. (2011). Cyclin E amplification/overexpression is a
Pietras, R. J., Poen, J. C., Gallardo, D., Wongvipat, P. N., Lee, H. J., & mechanism of trastuzumab resistance in HER2+breast cancer
Slamon, D. J. (1999). Monoclonal antibody to HER‐2/neureceptor patients. Proceedings of the National Academy of Sciences, 108(9),
modulates repair of radiation‐induced DNA damage and enhances 3761–3766.
radiosensitivity of human breast cancer cells overexpressing this Scaltriti, M., Rojo, F., Ocana, A., Anido, J., Guzman, M., Cortes, J., …
oncogene.CancerResearch,59(6),1347–1355. Baselga,J.(2007).Expressionofp95HER2,atruncatedformofthe
Pondé, N., Brandão, M., El‐Hachem, G., Werbrouck, E., & Piccart, M. HER2receptor,andresponsetoanti‐HER2therapiesinbreastcancer.
(2018). Treatment of advanced HER2‐positive breast cancer: 2018 JNCIJournaloftheNationalCancerInstitute,99(8),628–638.https://
andbeyond.CancerTreatmentReviews,67,10–20. doi.org/10.1093/jnci/djk134
1016/j.ctrv.2018.04.016 Scheuer,W.,Friess,T.,Burtscher,H.,Bossenmaier,B.,Endl,J.,&Hasmann,
Press,M.F.,Bernstein,L.,Thomas,P.A.,Meisner,L.F.,Zhou,J.Y.,Ma,Y.,… M.(2009).Stronglyenhancedantitumoractivityoftrastuzumaband
Flom, K. J. (1997). HER‐2/neu gene amplification characterized by pertuzumab combination treatment on HER2‐positive human xeno-
fluorescence in situ hybridization: Poor prognosis in node‐negative grafttumormodels.CancerResearch,69(24),9330–9336.
breast carcinomas. Journal of Clinical Oncology, 15(8), 2894–2904. Seidman, A. D., Berry, D., Cirrincione, C., Harris, L., Muss, H., Marcom,
 P. K., … Hudis, C. (2008). Randomized phase III trial of weekly
Pujol, A., Mosca, R., Farrés, J., & Aloy, P. (2010). Unveiling the role of comparedwithevery‐3‐weekspaclitaxelformetastaticbreastcancer,
networkandsystemsbiologyindrugdiscovery.TrendsInPharmaco- withtrastuzumab forall HER‐2overexpressors andrandom assign-
logical Sciences, 31(3), 115–123.  ment to trastuzumab or not in HER‐2 nonoverexpressors: Final
11.006 results of Cancer and Leukemia Group B protocol 9840. Journal of
Pupa,S.M.,Ménard,S.,Morelli,D.,Pozzi,B.,DePalo,G.,&Colnaghi,M.I. Clinical Oncology, 26(10), 1642–1649. 
(1993). The extracellular domain of the c‐erbB‐2 oncoprotein is 2007.11.6699
released from tumor cells by proteolytic cleavage. Oncogene, 8(11), Seo,A.N.,Lee,H.J.,Kim,E.J.,Jang,M.H.,Kim,Y.J.,Kim,J.H.,…Park,
2917–2923. S. Y. (2016). Expression of breast cancer stem cell markers as
Rabindran,S.K.,Discafani,C.M.,Rosfjord,E.C.,Baxter,M.,Floyd,M.B., predictors of prognosis and response to trastuzumab in HER2‐
Golas, J., … Wissner, A. (2004). Antitumor activity of HKI‐272, an positivebreastcancer.BritishJournalofCancer,114(10),1109–1116.
orally active, irreversible inhibitor of the HER‐2 tyrosine kinase. Sequist,L.V.,Yang,J.C.H.,Yamamoto,N.,O’Byrne,K.,Hirsh,V.,Mok,T.,
CancerResearch,64(11),3958–3965. … Schuler, M. (2013). Phase III study of afatinib or cisplatin plus
Raina,D.,Uchida,Y.,Kharbanda,A.,Rajabi,H.,Panchamoorthy,G.,Jin,C.,… pemetrexed in patients with metastatic lung adenocarcinoma with
Kufe, D. (2014). Targeting the MUC1‐C oncoprotein downregulates EGFR mutations. Journal of Clinical Oncology, 31(27), 3327–3334.
HER2activationandabrogatestrastuzumabresistanceinbreastcancer 
cells.Oncogene,33(26),3422–3431. Sharma,A.,&Jayanth,A.(2010).Neratinib,anirreversibleerbBreceptor
308 tyrosine kinase inhibitor, in patients with advanced erbB2‐positive
Razis, E., Bobos, M., Kotoula, V., Eleftheraki, A. G., Kalofonos, H. P., breastcancer.AdvancesinOncology,5(2),21–22.
Pavlakis,K.,…Fountzilas,G.(2011).Evaluationoftheassociationof Siegel,R.,Ma,J.,Zou,Z.,&Jemal,A.(2014).Cancerstatistics,2014.CA:A
PIK3CA mutations and PTEN loss with efficacy of trastuzumab CancerJournalforClinicians,64(1),9–29.
therapy in metastatic breast cancer. Breast Cancer Research and 21208
Treatment, 128(2), 447–456.  Slamon, D., Clark, G., Wong, S., Levin, W., Ullrich, A., & McGuire, W.
1572‐5 (1987).Humanbreastcancer:Correlationofrelapseandsurvivalwith
Rezaei,Z.,&Derakhshani,A.(2018).EvaluationofmiR‐340expressionin amplification of the HER‐2/neu oncogene. Science, 235(4785),
Bt474trastuzumabresistantcell.PaperpresentedattheALLERGY. 177–182.
Rezaei,Z.,Kordi‐Tamandani,D.,&Dastjerdi,K.(2018).Bonemorphogenic Sliwkowski,M.X.,Lofgren,J.A.,Lewis,G.D.,Hotaling,T.E.,Fendly,B.M.,
protein receptor type 1a (BMPR1A) and Caveolin‐1 contribute to & Fox, J. A. (1999). Nonclinical studies addressing the mechanism of
trastuzumab resistance of breast cancer cells. Paper presented at the actionoftrastuzumab(Herceptin).PaperpresentedattheSeminarsin
FEBSOPENBIO. oncology.
Rezaei, Z., Sebzari, A., Kordi‐Tamandani, D. M., & Dastjerdi, K. (2019). Solit,D.(2008).DevelopmentandapplicationofHsp90inhibitors.Drug
Involvement of the dysregulation of miR‐23b‐3p, miR‐195‐5p, miR‐ DiscoveryToday,13(1),38–43.
656‐5p,andmiR‐340‐5pintrastuzumabresistanceofHER2‐positive Sperinde,J.,Bachmeier,B.,Weidler,J.,Lie,Y.,Chenna,A.,Winslow,J.,…
breast cancer cells and system biology approach to predict their Petropoulos, C. (2016). Abstract P3‐07‐09: Quantitative p95HER2
targetsinvolvedinresistance.DNAandCellBiology,38(2),184–192. protein expression is predictive of trastuzumab response in HER2‐
 positivemetastaticbreastcancer.CancerResearch,76(4),Suppl.
RiusRuiz,I.,Vicario,R.,Morancho,B.,Morales,C.B.,Arenas,E.J.,Herter, Sperinde,J.,Huang,W.,Vehtari,A.,Chenna,A.,Kellokumpu‐Lehtinen,P.
S.,…Arribas,J.(2018).p95HER2–Tcellbispecificantibodyforbreast L., Winslow, J., … Joensuu, H. (2018). p95HER2 methionine 611
cancertreatment.ScienceTranslationalMedicine,10(461),eaat1445. carboxy‐terminal fragment is predictive of trastuzumab adjuvant
Saisana,M.,Griffin,S.M.,&May,F.E.B.(2016).ImportanceofthetypeI treatmentbenefitintheFinHertrial.ClinicalCancerResearch,24(13),
insulin‐likegrowthfactorreceptorinHER2,FGFR2andMET‐unamplified 3046–3052.
gastriccancerwithandwithoutRaspathwayactivation.Oncotarget,7(34), Stagg,J.,Divisekera,U.,McLaughlin,N.,Sharkey,J.,Pommey,S.,Denoyer,
54445–54462. D.,…Smyth,M.J.(2010).Anti‐CD73antibodytherapyinhibitsbreast
Sanabria‐Figueroa,E.,Donnelly,S.M.,Foy,K.C.,Buss,M.C.,Castellino,R. tumorgrowthandmetastasis.ProceedingsoftheNationalAcademyof
C., Paplomata, E., … Nahta, R. (2015). Insulin‐like growth factor‐1 Sciences,107(4),1547–1552.
receptor signaling increases the invasive potential of human Stagg,J.,Loi,S.,Divisekera,U.,Ngiow,S.F.,Duret,H.,Yagita,H.,…Smyth,
epidermal growth factor receptor 2‐overexpressing breast cancer M. J. (2011). Anti‐ErbB‐2 mAb therapy requires type I and II
10974652,
2020,
4,
Downloaded
from
by
Constructor
University,
Wiley
Online
Library
on
[16/05/2025].
See
the
Terms
and
Conditions
(
on
Wiley
Online
Library
for
rules
of
use;
OA
articles
are
governed
by
the
applicable
Creative
Commons
License
|
3156 DERAKHSHANIETAL.
interferons and synergizes with anti‐PD‐1 or anti‐CD137 mAb Wen,X.F.,Yang,G.,Mao,W.,Thornton,A.,Liu,J.,Bast,R.C.,&Le,X.F.
therapy. Proceedings of the National Academy of Sciences, 108(17), (2006).HER2signalingmodulatestheequilibriumbetweenpro‐and
7142–7147. antiangiogenicfactorsviadistinctpathways:ImplicationsforHER2‐
Sung,M.,Tan,X.,Lu,B.,Golas,J.,Hosselet,C.,Wang,F.,…Loganzo,F.(2018). targetedantibodytherapy.Oncogene,25(52),6986–6996.
Caveolae‐mediatedendocytosisasanovelmechanismofresistanceto org/10.1038/sj.onc.1209685
trastuzumab emtansine (T‐DM1). Molecular Cancer Therapeutics, 17(1), Xin,C.,Jing,D.,Jie,T.,Wu‐Xia,L.,Meng,Q.,&Ji‐Yan,L.(2015).Theexpression
243–253. differenceofinsulin‐likegrowthfactor1receptorinbreastcancerswith
Todeschini,P.,Cocco,E.,Bellone,S.,Varughese,J.,Lin,K.,Carrara,L.,… or without diabetes. Journal of CancerResearch and Therapeutics, 11(2),
Santin, A. D. (2011). Her2/neu extracellular domain shedding in 295–299.
uterine serous carcinoma: Implications for immunotherapy with Yamauchi,H.,O’Neill,A.,Gelman,R.,Carney,W.,Tenney,D.Y.,Hösch,S.,
trastuzumab. British Journal of Cancer, 105(8), 1176–1182. https:// &Hayes,D.F.(1997).Predictionofresponsetoantiestrogentherapy
doi.org/10.1038/bjc.2011.369 inadvancedbreastcancerpatientsbypretreatmentcirculatinglevels
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., ofextracellulardomainoftheHER‐2/c‐neuprotein.JournalofClinical
McDermott, D. F., … Sznol, M. (2012). Safety, activity, and immune Oncology,15(7),2518–2525.
correlates of anti–PD‐1 antibody in cancer. New England Journal of Yarden, Y., & Sliwkowski, M. X. (2001). Untangling the ErbB signalling
Medicine,366(366),2443–2454. network.NatureReviewsMolecularCellBiology,2(2),127–137.https://
Tóth,G.,Szöőr,Á.,Simon,L.,Yarden,Y.,Szöllősi,J.,&Vereb,G.(2016).The doi.org/10.1038/35052073
combination of trastuzumab and pertuzumab administered at approved Yu, S., Liu, Q., Han, X., Qin, S., Zhao, W., Li, A., & Wu, K. (2017).
doses may delay development of trastuzumab resistance by additively Development and clinical application of anti‐HER2 monoclonal and
enhancing antibody‐dependent cell‐mediated cytotoxicity. Paper pre- bispecificantibodiesforcancertreatment.ExperimentalHematology&
sentedattheMAbs. Oncology,6,31.
Tsang,R.Y.,&Finn,R.S.(2012).Beyondtrastuzumab:Noveltherapeutic Zabrecky, J. R., Lam, T., McKenzie, S. J., & Carney, W. (1991). The
strategiesinHER2‐positivemetastaticbreastcancer.BritishJournalof extracellular domain of p185/neu is released from the surface of
Cancer,106(1),6–13. human breast carcinoma cells, SK‐BR‐3. The Journal of Biological
Vahidian,F.,Duijf,P.H.G.,Safarzadeh,E.,Derakhshani,A.,Baghban- Chemistry,266(3),1716–1720.
zadeh, A., & Baradaran, B. (2019). Interactions between cancer Zhang,S.,Huang,W.C.,Li,P.,Guo,H.,Poh,S.B.,Brady,S.W.,…Yu,D.(2011).
stem cells, immune system and some environmental components: Combating trastuzumab resistance by targeting SRC, a common node
Friendsorfoes?ImmunologyLetters,208,19–29. downstreamofmultipleresistancepathways.NatureMedicine(NewYork,
1016/j.imlet.2019.03.004 NY,UnitedStates),17(4),461–469.
Valabrega,G.,Montemurro,F.,Sarotto,I.,Petrelli,A.,Rubini,P.,Tacchetti, Zhu,Y.,Li,L.,Zhang,G.,Wan,H.,Yang,C.,Diao,X.,…Zhong,D.(2016).
C., … Giordano, S. (2005). TGFα expression impairs Trastuzumab‐ Metabolic characterization of pyrotinib in humans by ultra‐perfor-
inducedHER2downregulation.Oncogene,24(18),3002–3010. mance liquid chromatography/quadrupole time‐of‐flight mass spec-
Verma,S.,Miles,D.,Gianni,L.,Krop,I.E.,Welslau,M.,Baselga,J.,…Blackwell, trometry.JournalofChromatographyB,1033‐1034,117–127.https://
K.(2012). TrastuzumabemtansineforHER2‐positiveadvanced breast doi.org/10.1016/j.jchromb.2016.08.009
cancer.NewEnglandJournalofMedicine,367(19),1783–1791.
Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N.,
Fehrenbacher, L., … Press, M. (2002). Efficacy and safety of
trastuzumab as a single agent in first‐line treatment of HER2‐ Howtocitethisarticle:DerakhshaniA,RezaeiZ,Safarpour
overexpressingmetastaticbreastcancer.JournalofClinicalOncology, H,etal.OvercomingtrastuzumabresistanceinHER2‐positive
20(3),719–726.
breastcancerusingcombinationtherapy.JCellPhysiol.
Wang, Z., Ruan, B., Jin, Y., Zhang, Y., Li, J., Zhu, L., … Wang, X. (2016).
2020;235:3142–3156.
IdentificationofKLK10asatherapeutictargettoreversetrastuzu-
mabresistanceinbreastcancer.Oncotarget,7(48),79494.
10974652,
2020,
4,
Downloaded
from
by
Constructor
University,
Wiley
Online
Library
on
[16/05/2025].
See
the
Terms
and
Conditions
(
on
Wiley
Online
Library
for
rules
of
use;
OA
articles
are
governed
by
the
applicable
Creative
Commons
License